# Socazolimab

Source: https://onco.cc/drugs/socazolimab/  
OnCo record `socazolimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Socazolimab is Lee's Pharmaceutical's PD-L1 antibody, in phase 3 trials in China for extensive-stage small cell lung cancer and recurrent cervical cancer.

## Summary

Socazolimab (ZKAB001), licensed by Lee's Pharmaceutical from Sorrento, is a fully human PD-L1 antibody. Its phase 3 programme in China includes first-line extensive-stage small cell lung cancer with chemotherapy and recurrent or metastatic cervical cancer; earlier trials included osteosarcoma. OnCo records its Chinese regulatory status only where a source states it.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: ZKAB001
- Modality: Anti-PD-L1 monoclonal antibody, intravenous
- Mechanism: Binds PD-L1 on tumour and immune cells so it cannot engage PD-1 on T cells.

## Sources

- ClinicalTrials.gov: trials of Socazolimab: https://clinicaltrials.gov/search?intr=ZKAB001

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- trials: [Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer](https://onco.cc/trials/nct06459687/)

---
JSON: https://onco.cc/api/v1/entities/socazolimab.json